Regulatory FDA, after turbulent year, leaves drugmakers guessing on its direction pharminent April 1, 2026
Policy / Pricing A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma pharminent April 1, 2026
Clinical Data ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower dose pharminent April 1, 2026
Clinical Data ACC 2026: Tonlamarsen lowers angiotensinogen without extra BP benefit pharminent April 1, 2026
Regulatory S16 Ep43: FDA Approval Insights: Rucaparib for BRCA Mutation-Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD pharminent March 31, 2026
M&A / Deals Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout pharminent March 31, 2026
M&A / Deals Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy pharminent March 31, 2026
Clinical Data PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease pharminent March 31, 2026
M&A / Deals Biogen, with $5.6B Apellis buy, builds out immunology offerings pharminent March 31, 2026
Other S16 Ep42: Variability and Innovation in Small Cell Lung Cancer Care: With Ticiana Leal, MD pharminent March 31, 2026
Other Drug Channels News Roundup, March 2026: Cigna’s 340B Workaround, Merck’s ARPA Surprise, Walgreens’ Automation Bet, Why Rebates Hurt Patients, and a DCI Team Photo pharminent March 31, 2026
Other Biotech IPOs stayed at slow pace, but grew larger in the first quarter of 2026 pharminent March 31, 2026
Regulatory S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD-Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD pharminent March 30, 2026
Clinical Data Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout pharminent March 30, 2026
Regulatory Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug pharminent March 30, 2026
Clinical Data Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline pharminent March 30, 2026
Market Access The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments pharminent March 30, 2026
